

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

PROVECTUS PHARMACEUTICALS INC  
Form SC 13G/A  
August 21, 2006

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G/A  
(Rule 13d-102)

Amendment No. 2

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1 (b) (c), AND (d)

Provectus Pharmaceuticals, Inc.

-----  
(Name of Issuer)

Common Stock, \$.001 par value

-----  
(Title of Class of Securities)

74373-F-100

-----  
(CUSIP Number)

July 3, 2006

-----  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 74373-F-100

13G/A

-----  
1. NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Richard Smithline

-----  
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a)   
(b)

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

2,349,929

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

6. SHARED VOTING POWER

0

7. SOLE DISPOSITIVE POWER

2,349,929

8. SHARED DISPOSITIVE POWER

0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,349,929

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.0%

12. TYPE OF REPORTING PERSON\*

IN

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 74373-F-100

13G/A

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Centrecourt Asset Management LLC

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

United States

-----  
5. SOLE VOTING POWER  
2,237,429  
-----  
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
6. SHARED VOTING POWER  
0  
-----  
7. SOLE DISPOSITIVE POWER  
2,237,429  
-----  
8. SHARED DISPOSITIVE POWER  
0  
-----

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,237,429  
-----

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

-----  
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
5.8%  
-----

12. TYPE OF REPORTING PERSON\*  
OO  
-----

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 74373-F-100 13G/A

-----  
1. NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)  
CAMOFI Master LDC  
-----  
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a)   
(b)

-----  
3. SEC USE ONLY  
-----

-----  
4. CITIZENSHIP OR PLACE OF ORGANIZATION  
Cayman Islands  
-----

5. SOLE VOTING POWER  
2,237,429  
-----  
NUMBER OF  
6. SHARED VOTING POWER

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

SHARES  
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

0
7. SOLE DISPOSITIVE POWER
2,237,429
8. SHARED DISPOSITIVE POWER
0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,237,429

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.8%

12. TYPE OF REPORTING PERSON\*

OO

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

Item 1.

(a) Name of Issuer.

Provectus Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices.

7327 Oak Ridge Hwy., Suite A  
Knoxville, TN 37931

Item 2.

(a) Name of Person Filing.

This Schedule 13G/A is being filed with respect to shares of Common Stock of the Issuer which are beneficially owned by Richard Smithline ("Mr. Smithline"), Centrecourt Asset Management LLC ("Centrecourt") and CAMOFI Master LDC ("CAMOFI") (collectively, the "Reporting Persons").

The Reporting Persons are making a joint filing because they may be deemed a group pursuant to Section 13 of the Securities Exchange Act of 1934. The Reporting Persons do not affirm the existence of such a group.

(b) Address of Principal Business Office or, if none, Residence.

The principal business address of each of Mr. Smithline and Centrecourt is:

## Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

350 Madison Avenue, 8th Floor  
New York, NY 10017

The principal business address of CAMOFI is:

90 Fort Street, 5th Floor  
Box 32021 SMB  
Grand Cayman, Cayman Islands

(c) Citizenship.

Mr. Smithline is a United States citizen.

Centrecourt is organized and existing in Delaware.

CAMOFI is organized and existing in the Cayman Islands.

(d) Title of Class of Securities.

Common Stock, \$0.001 par value per share

(e) CUSIP Number.

74373-F-100

Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under Section 15 of the Act.
- (b)  Bank as defined in Section 3(a)(6) of the Act.
- (c)  Insurance Company as defined in Section 3(a)(19) of the Act.
- (d)  Investment Company registered under Section 8 of the Investment Company Act.
- (e)  Investment Adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E).
- (f)  Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F).
- (g)  Parent holding company, in accordance with Sec. 240.13d-1(b)(ii)(G).
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i)  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
- (j)  Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Sec. 240.13d-1(c), check this box .

Item 4. Ownership

(a) Amount Beneficially Owned.

Mr. Smithline: 2,349,929 (comprised of 112,500 shares of Common Stock underlying Warrants, 104,096 shares of Common Stock held by CAMOFI, of which Mr. Smithline is a director, 800,000 shares of Common Stock, underlying Convertible Debentures held by CAMOFI, of which Mr. Smithline is a director and 1,333,333 shares of Common Stock underlying Warrants held by CAMOFI, of which Mr.

## Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

Smithline is a Director.

Centrecourt: 2,237,429 (comprised of 104,096 shares of Common Stock held by CAMOFI, of which Centrecourt is the investment manager, 800,000 shares of Common Stock underlying Convertible Debentures held by CAMOFI, of which Centrecourt is the investment manager and 1,333,333 shares of Common Stock underlying Warrants held by CAMOFI, of which Centrecourt is the investment manager).

CAMOFI: 2,237,429 (comprised of 104,096 shares of Common Stock, 800,000 shares of Common Stock, underlying Convertible Debentures and 1,333,333 shares of Common Stock underlying Warrants).

- (b) Percent of Class. Mr. Smithline: 6.0%  
Centrecourt: 5.8%  
CAMOFI: 5.8%
- (c) Number of shares as to which each such person has
- (i) sole power to vote or to direct the vote: Mr. Smithline: 2,349,929  
Centrecourt: 2,237,429  
CAMOFI: 2,237,429
- (ii) shared power to vote or to direct the vote: Mr. Smithline: 0  
Centrecourt: 0  
CAMOFI: 0
- (iii) sole power to dispose or to direct the disposition of:  
Mr. Smithline: 2,349,929  
Centrecourt: 2,237,429  
CAMOFI: 2,237,429
- (iv) shared power to dispose or to direct the disposition of:  
Mr. Smithline: 0  
Centrecourt: 0  
CAMOFI: 0

### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

See Item 4(a) above, which is incorporated by reference herein.

### Item 8. Identification and Classification of Members of the Group.

The Reporting Persons may be deemed to constitute a group with one

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

another pursuant to Section 13 of the Securities Exchange Act of 1934. The Reporting Persons do not affirm the existence of such a group.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 3, 2006

/s/ Richard Smithline

-----  
Richard Smithline

Centrecourt Asset Management LLC

By: /s/ Richard Smithline

-----  
Name: Richard Smithline  
Title: Managing Member

CAMOFI Master LDC

By: /s/ Richard Smithline

-----  
Name: Richard Smithline  
Title: Director

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

EXHIBIT A

AGREEMENT

JOINT FILING OF SCHEDULE 13G/A

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

The undersigned hereby agree jointly to prepare and file with regulatory authorities a Schedule 13G/A and any amendments thereto reporting each of the undersigned's ownership of securities of Provectus Pharmaceuticals, Inc. and hereby affirm that such Schedule 13G/A is being filed on behalf of each of the undersigned.

Date: July 3, 2006

/s/ Richard Smithline

-----  
Richard Smithline

Centrecourt Asset Management LLC

By: /s/ Richard Smithline

-----  
Name: Richard Smithline  
Title: Managing Member

CAMOFI Master LDC

By: /s/ Richard Smithline

-----  
Name: Richard Smithline  
Title: Director